Data shows daratumumab monotherapy induced durable responses in heavily pre-treated relapsed or refractory multiple myeloma patients

Genmab A/S has announced the New England Journal of Medicine (NEJM) has published the full data set from the initial Phase I/II study with daratumumab monotherapy treating patients with relapsed… Source link